Heart. 2018 Dec 4. pii: heartjnl-2018-313955. doi: 10.1136/heartjnl-2018-313955.
Lees JS1,2, Chapman FA2, Witham MD3, Jardine AG1,2, Mark PB1,2.
- Arterial stiffness reduced if use at least 2,000 IU of Vitamin D for 4 months – meta-analysis Dec 2019
Items in both categories Cardiovascular and Vitamin K are listed here:
- Cardiovascular Disease prevented by Vitamin K2-4 when enough is used – RCT review Sept 2020
- Calcium Supplementation is OK provided you also take Vitamin K – Feb 2019
- Vitamin K reduces calcification (reported yet again) – Feb 2019
- Vitamin K (across all dose sizes and types) decrease Vascular Stiffness – meta-analysis - Dec 2018
- Vitamin D and Vitamin K together fight CVD Part 1- Pizzorno
- Vitamin K, Cardiovascular and interactions with Vitamin D and Vitamin A – Pizzorno July 2018
- Mortality associated with Vitamin K insufficiency (PREVEND Study) – Nov 2017
- Intracranial arterial calcification in 85 percent of ischemic strokes (Vitamin K and Vitamin D should help) – Oct 2017
- Decalcify Aortic Valve – 3 year trial with 1 mg of Vitamin K and 5,000 IU of Vitamin D – 2021
- Cardiovascular problems reduced by low dose aspirin and perhaps Omega-3 (also Vit K) – Sept 2017
- Athletes maximal cardiac output increased 12 percent with Vitamin K2 – RCT July 2017
- Fast blood flow 6.8 X more likely if high vitamin D AND high vitamin K – Aug 2017
- Low Vitamin K2 is as risky as smoking for heart disease - Oct 2016
- Cardiovascular death: 9 percent due to hypertension or air pollution, 7 percent: low Vitamin K2 or smoking – Oct 2016
- Decreased need for warfarin after Vitamin D levels optimized – RCT May 2016
- Cardiovascular calcification prevented by Omega-3, Magnesium, Vitamin K, and Vitamin D – April 2015
- The health benefits of vitamin K – Oct 2015
- If you must take statins and want to avoid hardening of arteries, take vitamin K2 – RCT May 2015
- Vitamin K2 decreases arterial stiffness (cleans arteries) – RCT Feb 2015
- Hypothesis: Vitamin K will reduce prostate blood vessel problems – Jan 2015
- Increased Vitamin K2 reduces the problems of excess Calcium – Nov 2013
- Cholesterol, Vitamins D3 and K2, heart disease, sulfates, LDL, – Masterjohn Interview Jan 2013
- Soft Bones, Hard Arteries, Vitamin D, Vitamin K2 and antibiotics – Sept 2012
- Vitamin D – vitamin K – bittle bones – hardened arteries – LEF Sept 2010
Vascular stiffness (VS) and vascular calcification (VC) are surrogate markers of vascular health associated with cardiovascular events. Vitamin K-dependent proteins (VKDP) are associated with VS and VC and require vitamin K for activity. We conducted a systematic review and meta-analysis of: (1) the effect of vitamin K supplementation on VS and VC and (2) association of inactive VKDP levels with incident cardiovascular disease and mortality.
Two authors searched MEDLINE and Embase databases and Cochrane and ISRCTN registries for studies of vitamin K clinical trials that measured effects on VC, VS or VKDP and longitudinal studies assessing effect of VKDP on incident CVD or mortality. Random effects meta-analyses were performed.
Thirteen controlled clinical trials (n=2162) and 14 longitudinal studies (n=10 726) met prespecified inclusion criteria. Vitamin K supplementation was associated with significant reduction in VC (-9.1% (95% CI -17.7 to -0.5); p=0.04) and VKDP (desphospho-uncarboxylated matrix Gla protein; -44.7% (95% CI -65.1 to -24.3), p<0.0001) and uncarboxylated osteocalcin; -12.0% (95% CI -16.7 to -7.2), p<0.0001) compared with control, with a non-significant improvement in VS. In longitudinal studies with median follow-up of 7.8 (IQR 4.9-11.3) years, VKDP levels were associated with a combined endpoint of CVD or mortality (HR 0.45 (95% CI 0.07 to 0.83), p=0.02).
Supplementation with vitamin K significantly reduced VC, but not VS, compared with control. The conclusions drawn are limited by small numbers of studies with substantial heterogeneity. VKDP was associated with combined endpoint of CVD or mortality. Larger clinical trials of effect of vitamin K supplementation to improve VC, VS and long-term cardiovascular health are warranted.
TRIAL REGISTRATION NUMBER: CRD42017060344.